-+ 0.00%
-+ 0.00%
-+ 0.00%

Ligand, Viking dispute TR-Beta program termination under license agreement

PUBT·04/30/2026 21:38:35
Listen to the news
Ligand, Viking dispute TR-Beta program termination under license agreement
  • Ligand delivered notice to Viking Therapeutics terminating TR-Beta Program under 2014 master license agreement, citing an alleged material breach tied to development and commercialization efforts.
  • Termination set to take effect May 4, 2026.
  • Action would end Viking licenses for TR-Beta assets, including VK2809 and VK0214.
  • License terms call for Viking to grant Ligand a non-exclusive, worldwide, royalty-bearing, sublicensable license to Viking-controlled IP needed for TR-Beta products, with royalties in low single digits.
  • Viking disputes Ligand’s termination right; Ligand signaled it will enforce its position, setting up a potential legal fight.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000886163-26-000027), on April 30, 2026, and is solely responsible for the information contained therein.